
    
      This is a Phase Ib dose escalation and Phase II study in patients with DLBCL harboring
      mutations in CD79A/B or of the ABC subtype. Pre-screening for mutations in CD79A/B or the ABC
      subtype will be required, as it is anticipated that both patient groups may receive clinical
      benefit from the combination of AEB071 and EVEROLIMUS.
    
  